2-Methoxyestradiol Exhibits a Biphasic Effect on VEGF-A in Tumor Cells and Upregulation Is Mediated Through ER-α: A Possible Signaling Pathway Associated with the Impact of 2-ME2 on Proliferative Cells  by Banerjee, Samarendra N. et al.
2-Methoxyestradiol Exhibits a Biphasic Effect on VEGF-A in Tumor
Cells and Upregulation Is Mediated Through ER-a: A Possible
Signaling Pathway Associated with the Impact of 2-ME2 on
Proliferative Cells1
Samarendra N. Banerjee2,3, Krishanu Sengupta2, Snigdha Banerjee, Neela K. Saxena and
Sushanta K. Banerjee
Cancer Research Unit, V.A. Medical Center, Kansas City, KS, USA; Division of Hematology and Oncology,
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
Abstract
2-Methoxyestradiol (2-ME2) was reported to elicit both
stimulation and inhibition of tumor angiogenesis and
growth depending on the dosage used. However, the
mechanism(s) of the biphasic action of 2-ME2 has been
elusive. Here we describe a regulatory role of vascular
endothelial growth factor-A (VEGF-A) in the biphasic
effects on estrogen receptor (ER)+ GH3 rat pituitary
tumor cells and MCF-7 human breast tumor cells
depending on the dosage of 2-ME2 used. We observed
that acute exposure to 2-ME2, irrespective of dosage,
did not alter cellular proliferation, but enhanced the
VEGF-A mRNA level. As the treatment duration in-
creased, biphasic effect was elicited. A concentration
of 1 MM 2-ME2 increased both cell proliferation and
VEGF-A levels in these cells, whereas higher doses
exhibited reversed impact. A low dose of 2-ME2 also
increased the VEGF-A mRNA expression in ER-A–
transfected human mammary epithelial cells (HMECs).
The effect was reversed in ER cells. The enhanced
expression of VEGF-A mRNA could be blocked by the
pure estrogen antagonist, ICI 182,780, and reveal that
the upregulation of VEGF-A expression by 2-ME2 is
mediated through ER-A. Furthermore, the biphasic
effect of 2-ME2 on cell proliferation can be modulated
by administrating VEGF-A antibodies or VEGF-A
proteins. Studies also demonstrate that the VEGF-A
protein, induced by 2-ME2, is functionally active and
upregulates the proliferation of adjacent endothelial
cells.
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Introduction
2-Methoxyestradiol (2-ME2) is an endogenous estrogen (i.e.,
17b-estradiol) metabolite produced by sequential hydroxyl-
ation of parent compounds followed by methylation by
catechol-O-methyltransferase in the liver [1–3]. 2-ME2 is syn-
thesized in mammalian tissues and represents a crucial step in
the elimination of potentially damaging catechol estrogen from
proliferating cells [4]. It has strong binding affinity for sex
hormone–binding globulin (SHBG) in the blood [2,5]. However,
unlike the parent compounds and their other metabolites, this
molecule has a low affinity for estrogen receptors (ERs), thus
having minimal estrogenic activity [1,2]. 2-ME2 has been
considered as a promising anticancer drug candidate [6] as it
reveals antiproliferative and apoptotic activities against rapidly
growing tumors and endothelial cells by triggering the induction
or suppression of genes that elicit apoptosis or cell proliferation
[3,7–12]. 2-ME2 reduced the cell motility, migration, and ad-
hesion of various drug-sensitive and drug-resistant tumor cell
lines [13]. It suppressed the growth of certain murine tumors by
inhibiting tumor cell proliferation and angiogenesis [10,14,15].
Furthermore, a Phase I clinical trial of this compound showed
no serious drug-related unpleasant effects, while exhibiting a
significant reduction in bone pain and analgesic intake in some
breast cancer patients [6]. A Phase II randomized trial of 2-ME2
in hormone-refractory prostate cancer patients demonstrated
the stabilization and/or reduction of prostate-specific antigen
after treatment [6].
Despite the potential anticancer features of 2-ME2, recent
studies have revealed dose-dependent dual effects of this
compound. For example, 1-mM doses (or less) of 2-ME2 exhibit
Abbreviations: 2-ME2, 2-methoxyestradiol; BCEC, bovine capillary endothelial cell; CSPD,
disodium 3-(4-methoxyspiro{1,2-dioxetane-3,2-(5-chloro)tricyclo[3.3.1.1,7]decan}-4-yl)phenyl
phosphate; DIG, digoxigenin; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate-
dehydrogenase; HMEC, human mammary epithelial cell; MOPS, 3-(N-morpholino)pro-
panesulfonic acid; 1  PBS, 1  phosphate-buffered saline; PMSF, phenylmethylsulfonyl
fluoride; VEGF-A, vascular endothelial growth factor-A; huMAb-VEGF-A, humanized mono-
clonal antibody directed against VEGF-A
Address all correspondence to: Sushanta K. Banerjee, PhD, Cancer Research Unit, Research
Division 151, V.A. Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA.
E-mail: sbanerjee2@kumc.edu
1This work is supported by NIH/NCI CA87680, V.A. merit review grant, the Midwest Bio-
medical Research Foundation grant, the EntreMed, Inc. research grant, and the University of
Kansas Medical Center departmental research grant.
2Both authors have equal contributions to this work.
3Present address: Zoology Department, Rammohan College, Kolkata, India.
Received 18 June 2003; Revised 29 July 2003; Accepted 5 August 2003.
Copyright D 2003 Neoplasia Press, Inc. All rights reserved 1522-8002/03/$25.00
Neoplasia . Vol. 5, No. 5, September/October 2003, pp. 417–426 417
www.neoplasia.com
RESEARCH ARTICLE
proliferative effects in MCF-7 breast tumor cells, whereas
higher doses of 2-ME2 inhibit cell proliferation [12]. Similarly,
in vivo studies have shown both stimulation and inhibition of
tumor growth by this compound depending on the dosage
used [14,15]. Together, these studies suggest a complex
nature of action of this molecule, and indicate that in addition
to the known signaling pathways [6,16–20], there may be
additional pathways, which have not yet been elucidated,
that exert biphasic effects of 2-ME2.
2-ME2 is a potent inhibitor of estrogen-induced tumor
angiogenesis and tumorigenesis in F344 rat pituitaries, and
this inhibitory activity is strongly associated with the down-
regulation of vascular endothelial growth factor-A (VEGF-A)
expression [14]. Subsequently, similar results were ob-
served by other studies in the SCID mouse model [21], and
suggested that the inhibition of the local release of VEGF-A
was an important event required to block tumor growth.
However, the direct involvement of VEGF-A during the
dose-dependent modulation of tumor cell growth and prolif-
eration by 2-ME2 is unknown. The aim of the present study
was to investigate the dose-dependent effect of 2-ME2 on
VEGF-A expression in different cell lines, either ER+ or ER,
and to correlate these results with cell proliferation to deter-
mine if ER was involved in this process. Moreover, an
additional aim was to evaluate the protective role of VEGF-
A, if any, against cell death exerted by 2-ME2.
Materials and Methods
Chemicals
2-ME2 was a gift from EntreMed, Inc. (Rockville, MD). A
stock solution was prepared in absolute ethanol and stored
at 20jC. Dulbecco’s modified Eagle’s medium (DMEM),
human recombinant VEGF-A protein, VEGF monoclonal
antibody, and cell dissociation solution were purchased from
Sigma (St. Louis, MO). Fetal bovine serum (FBS) was
purchased from HyClone Laboratories (Logan, UT). BrdU
enzyme-linked immunosorbent assay (ELISA) kits and
digoxigenin (DIG) high-prime DNA labeling kits were pur-
chased from Roche Applied Science (Indianapolis, IN).
[3H]Thymidine (specific activity: 84,000 mCi/mmol) was pur-
chased from Amersham Life Science (Arlington, IL).
Cell Lines and Culture Conditions
GH3 rat pituitary tumor cells, human breast tumor–
derived MCF-7 epithelial tumor cells, and MIA-PaCa-2
pancreatic adenocarcinoma cells were obtained from the
American Type Cell Culture Collection (ATCC; Rockville,
MD). ER-a–transfected or vehicle-transfected or nontrans-
formed mammary epithelial cells were gifts from Dr. Debo-
rah Zajchowski (Berlex Biosciences, Richmond, CA),
Bovine capillary endothelial cells (BCECs) were kindly
provided by Dr. Dipak K. Banerjee (University of Puerto
Rico, San Juan, PR). GH3 cells were routinely maintained in
DMEM supplemented with 15% horse serum and 2.5%
FBS. MCF-7 cells and BCECs were grown in DMEM,
supplemented with 10% FBS and 1% penicillin–streptomy-
cin (Sigma). Transfected cells were grown in chemically
defined medium. Cells were passed weekly, at a split ratio
of 1:4, and subcultured into 25-cm2 T-flasks. The cultures
were maintained in a humidified incubator with 5% CO2 at
37jC.
[3H]Thymidine Incorporation Assay
[3H]Thymidine was added to each control and treated well
at a rate of 0.5 mCi/ml (1 ml/well) 24 hours prior to harvesting
the cells. Cells were harvested in glass fiber filter papers
using a Millipore vacuum system (Millipore, Bedford, MA)
and radioactive thymidine incorporation was measured using
a liquid scintillation counter.
BrdU Cell Proliferation Assay
The BrdU cell proliferation assay was performed accord-
ing to the instructions provided by the manufacturer. Briefly,
experimental cells were exposed to BrdU for 24 hours, and
then fixed in FixDenat solution for 20 minutes at room
temperature. Cells were incubated with anti–BrdU-POD
solution for 90 minutes at room temperature followed by
washing three times with washing solution. Cells were incu-
bated with substrate solution until color development was
sufficient for photometric detection.
mRNA Extraction and Northern Blot Analysis
Total RNA from different cells was extracted using the
Trizol reagent (Life Technologies, Grand Island, NY) extrac-
tion procedure, as described previously [22]. Tenmicrograms
of total RNA was fractionated by electrophoresis in 1%
agarose gels containing formaldehyde and transferred to
super charge nylon membrane (Schleicher and Schuell,
Keene,NH).Membraneswere hybridizedwith nonradioactive
polymerase chain reaction–generated DIG-labeled VEGF-A
and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
gene-specific probes and washed according to the protocol
provided by the manufacturer of the DIG high-prime DNA
labeling and detection kit. VEGF-A and GAPDH mRNA
expression were quantitated by densitometric analyses using
the Gel Expert software program (NucleoTech, San Fran-
cisco, CA).
Western Blot Analysis
Immunoreactive proteins corresponding to VEGF or actin
were identified from total protein by Western immunobloting
using specific monoclonal antibodies. The protein extraction
and Western blot technique were essentially carried out as
described previously [23]. Signals were quantitated by scan-
ning the film using Scan Jet scanner, and the intensity of
each band was measured using the Gel Expert software
(NeucleoTech).
Indirect Coculture
Indirect coculture was performed using the Transwell
culture system (0.4 mm pore size; Corning Coster, Cam-
bridge, MA). BCECs (1  105) were seeded in the lower
chamber, and allowed to grow in DMEM with 10% FBS until
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the culture became 60% confluent before being maintained
in phenol red–free DMEM devoid of FBS for 24 hours. In a
separate culture, GH3 cells were grown in DMEM with 10%
FBS in the presence or absence of 1 or 5 mM 2-ME2 for
3 days. Following 2-ME2 treatment, cells were grown in fresh
medium containing no serum for 4 hours; the media were
collected, centrifuged at 250g for 2 minutes, and added into
the upper chambers of the Transwell systems along with
detached GH3 cells. The cells were detached by a nonen-
zymatic cell dissociation solution. The coculture was main-
tained for 24 hours. Radioactive thymidine was added into
the culture prior to 24 hours of the cell proliferation assay.
BCECs cultured in the same series without tumor cells in the
upper chamber served as negative controls.
Results
Differential Response of 2-ME2 on the Proliferation of ER
+
and ER Tumor Cells
Existing evidence indicates that 2-ME2 perturbs the pro-
liferation of different cells, including a variety of tumor cells,
endothelial cells, and vascular smooth muscle cells [17,24].
However, dose-dependent responses are diverged from cell
to cells. Comparative studies have demonstrated that the
IC50 value for 2-ME2 is different for different cell lines [17,25].
Paradoxically, discrepancies in IC50 values for the same cell
type have also been reported [17,25]. Furthermore, recent
studies have reported a biphasic effect of 2-ME2 on MCF-7
cell proliferation [12]. These variable findings suggested that
the culture conditions might be one of the crucial factors for
this discrepancy. Therefore, in the present studies, we first
evaluated the impact of 2-ME2 on radioactive thymidine
incorporation into the replicating DNA in ER+ GH3 rat pitu-
itary tumor cells and MCF-7 breast tumor cells, and ER
MIA-PaCa-2 pancreatic adenocarcinoma cells. After 3 days,
5 to 10 mM concentrations of 2-ME2 significantly inhibited
radioactive thymidine incorporation in both ER+ and ER
tumor cells (Figure 1). The radioactive thymidine incorpora-
tion was reduced compared to untreated controls, by 1.8-,
3.9-, and 2.5-fold in 2-ME2 (5 mM)–treated GH3, MCF-7, and
MIA-PaCa-2 cells, respectively (Figure 1). In contrast, after 3
days of exposure to 1 mM 2-ME2, radioactive thymidine
incorporation was significantly (paired two-tailed Student’s
t-test) elevated by 1.3-fold in GH3 and 1.6-fold in MCF-7
cells, compared to vehicle-treated cells (Figure 1). The effect
was reversed in MIA-PaCa-2 cells.
The modulation of radioactive thymidine incorporation
into the DNA of either cell by 2-ME2 is time-dependent, being
undetected within 2 to 24 hours of exposure (data not
shown). Moreover, the impact of 2-ME2 on proliferation is
also dependent upon the cell density being minimal at higher
densities (i.e., 70–80% confluent culture).
Proliferation-Dependent Changes in VEGF-A mRNA and
Protein Expression
Vascular endothelial growth factors are able to modulate
the proliferation of both normal and tumor cells including
endothelial cells [26], ductal epithelial cells of the pancreas
[27,28], and gastric adenocarcinoma cells [29]. Moreover,
Figure 1. Dose-dependent effects of 2-ME2 on cell proliferation in rat pituitary
tumor–derived GH3 tumor cells, human breast tumor–derived MCF-7 tumor
cells, and human pancreatic adenocarcinoma MIA-PaCa-2 cells. Exponen-
tially growing cells in DMEM containing 10% serum were exposed to various
concentrations of 2-ME2 for 3 days, and cell proliferation was determined by
measuring the [3H]thymidine incorporation into DNA. (A) GH3 rat pituitary
tumor cells. (B) MCF-7 human breast tumor cells. (C) MIA-PaCa-2 pancreatic
adenocarcinoma cells. Data displayed as mean ± SD from three separate
experiments. P value was determined by Student’s t-test. *P < .05 vs control;
**P < .01 vs control; ***P < .001 vs control.
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our previous studies as well as recent in vitro studies have
demonstrated that VEGF-A expression was downregulated
by 2-ME2 during the inhibition of estrogen-induced rat pitu-
itary tumor growth [14,30]. We investigated the status
of VEGF-A mRNA and proteins during the biphasic effects
of 2-ME2 on DNA synthesis in ER
+ GH3 rat pituitary tumor
cells and MCF-7 human breast tumor cells, and ER MIA-
PaCa-2 pancreatic adenocarcinoma cells. 2-ME2, at 1 mM
concentration, significantly enhanced VEGF-A mRNA ex-
pression in ER+ GH3 and MCF-7 cells (Figure 2, A–D). In
contrast, expression in MIA-PaCa-2 cells was reversed
(Figure 2, E and F ). Higher concentrations (i.e., 5 or 10 mM
concentrations) of 2-ME2 significantly (paired two-tailed Stu-
dent’s t-test) decreased the VEGF-A mRNA expression in
GH3 cells and MIA-PaCa-2 cells compared to vehicle-trea-
ted controls (Figure 2). Ironically, the effects on VEGF-A
mRNA expressions were apparently undetected by Northern
blot analyses in MCF-7 cells (Figure 2,C andD). This may be
due to the low-level constitutive expression of VEGF-A
mRNA.
The effect on the expression of VEGF-A at the protein
level indicated an induction in GH3 and MCF-7 cells at 1 mM
2-ME2 concentration. In contrast, the impact of 2-ME2 at
higher doses was not markedly severe in GH3 and MCF-7
cells as observed in MIA-PaCa-2 cells (Figure 3).
Acute treatment of GH3 cells with various doses (i.e., 1,
5, or 10 mM) of 2-ME2 augments the VEGF-A mRNA levels
significantly after 4 hours of exposure, compared to control
Figure 2. Dose-dependent effects of 2-ME2 on VEGF-A mRNA expressions in GH3 rat pituitary tumor cells, MCF-7 human breast tumor cells, and MIA-PaCa-2
human pancreatic adenocarcinoma cells. Exponentially growing cells in DMEM containing 10% serum were exposed to various concentrations of 2-ME2 for 3 days,
and VEGF-A mRNA expression was determined by Northern blot analyses using nonradioactive DIG-labeled probe. (A), (C), and (E) represent VEGF-A and
GAPDH mRNA levels in untreated and treated GH3, MCF-7, and MIA-PaCa-2 cells respectively. (B), (D), and (F) represent arbitrary values indicating VEGF-A
mRNA levels. Data displayed as mean±SD from three separate experiments. P value was determined by Student’s t-test. *P < .05 vs control; **P < .01 vs control.
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(Figure 4). The expression was steadily and significantly
increased until 24 hours (Figure 4). The impact was max-
imal at the 1-mM dose (Figure 4B). Similar effects were also
observed in MCF-7 cells. However, the effect was unde-
tected in MIA-PaCa-2 cells (data not shown).
The Upregulation of VEGF-A mRNA Expression by 2-ME2
Is Meditated Through ERs
To determine whether 2-ME2 (1 mM)–induced upregula-
tion of VEGF-A mRNA expressions in ER+ cells was medi-
ated through an ER, GH3 cells were exposed to a pure
antiestrogen, ICI 182,780, concomitantly with 2-ME2 (1 mM)
for 3 days (Figure 5). The ICI 182,780 completely precluded
the induction of VEGF-A mRNA expression to the basal
levels by 2-ME2 in GH3 cells (Figure 5), indicating that the
2-ME2–induced VEGF-A mRNA upregulation is ER-depen-
dent. To further confirm the involvement of ER, the impact of
2-ME2 on ER-a–transfected human mammary epithelial
cells (ER-a+ HMECs) was evaluated. ER-a+ HMECs and
vector only–transfected cells were exposed to 1 mM 2-ME2
Figure 3. Chronic effects of various doses of 2-ME2 on the levels of VEGF-A protein in different tumor cell lines. Exponentially growing cells (i.e., GH3 or MCF-7 or
MIA-PaCa-2 cells) in DMEM containing 10% serum were exposed to one of the three concentrations (i.e., 1.0, 5.0, and 10.0 M) of 2-ME2 for 3 days. After
exposure, proteins were extracted from different cells and 50 g of total cell lysates was prepared for Western immunoblot analysis. VEGF-A protein levels were
determined by chemiluminescent immunoblotting with monoclonal anti –human VEGF-A. The photograph exhibits a single representative blot showing VEGF-A
and -actin levels in untreated and 2-ME2– treated cells.
Figure 4. Time- and dose-dependent effects of 2-ME2 on VEGF-A mRNA expression in GH3 cells. Semiconfluent GH3 cells were exposed to various doses of
2-ME2 (i.e., 1, 5, and 10 M) for different times as indicated; 0.1% ethanol – treated culture was considered as the untreated control (C). After treatment, total
RNA was extracted and VEGF-A mRNA expression was determined by Northern blot analyses using nonradioactive DIG-labeled probe. Data displayed as
mean ± SD from three separate experiments. (A) Single representative blot showing VEGF-A and GAPDH expressions in untreated and 2-ME2– treated cells.
(B) Arbitrary values indicate VEGF-A mRNA level. Data displayed as mean±SD in each case. P value was determined by Student’s t-test. P < .01 compared to
untreated control.
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for 3 days, and VEGF-AmRNA levels were determined using
Northern blot analyses. As expected, VEGF-A mRNA levels
were elevated significantly in ER-a+ HMECs (Figure 6),
whereas the effect was reversed in ER-a HMECs (data
not shown). These studies demonstrate that the upregulation
of VEGF-A mRNA by 2-ME2 is mediated through ER-a.
Impact of Anti –VEGF-A Antibodies and Recombinant
Human VEGF-A Proteins on the Effects of 2-ME2
A previous study [31] has shown that VEGF-A is able to
protect endothelial cells from the antiangiogenic therapy of
decetaxel, a related compound of taxane extracted from
Taxus baccata. However, 2-ME2 could diminish the protec-
tive effect of VEGF [31], and encourages us to determine
whether the upregulation of VEGF induced by 2-ME2 was
functionally relevant. To test this, exponentially growing cells
in DMEM containing 10% FBS were exposed to either 1 mM
2-ME2 in the presence or absence of huMAb-VEGF-A (hu-
manized monoclonal antibody directed against VEGF-A; 100
ng/ml), or 5 or 10 mM concentrations of 2-ME2 with or without
recombinant VEGF-A protein. After 3 days of exposure, cell
proliferation was measured using BrdU ELISA. Similar to the
radioactive thymidine incorporation studies (Figure 1), BrdU
incorporations were elevated in both GH3 and MCF-7 cells
after exposure to 1 mM 2-ME2 for 3 days, whereas higher
doses (i.e., 5 or 10 mM) significantly reduced BrdU incorpo-
rations in both cell types (Figure 7). Simultaneous addition of
monoclonal anti–VEGF antibody with 1 mM 2-ME2 partially,
but significantly, reduced (Student’s two-tail test) BrdU in-
corporation in GH3 and MCF-7 cells when compared to the
incorporation seen with 2-ME2 alone. In contrast, when cells
were exposed to higher doses of 2-ME2, along with recom-
binant VEGF-A protein (10 ng/ml), the inhibitory action of
2-ME2 was reduced significantly (Student’s two-tail test) by
1.9-fold in GH3 and 2.1-fold in MCF-7 cells (Figure 7).
Together, these results indicate the involvement of VEGF-A
in the modulation of tumor cell proliferation by 2-ME2.
2-ME2–Induced VEGF-A Protein Secretion by Tumor Cells
Increased Endothelial Cell Proliferation Through a Paracrine
Pathway
To determine if the 2-ME2–induced release of VEGF-A
from tumor cells can modulate neighboring endothelial cells,
we carried out an indirect coculture experiment. BCECs were
grown in the lower chamber for 48 hours, or until the culture
became 60% confluent, and then grown for an additional
24 hours in serum-free conditions that kept the environment
growth hormone–free. In a separate culture, GH3 cells were
grown in DMEM containing 10% serum and 1 or 5 mM 2-ME2
for 3 days. After treatment, the GH3 cells with medium were
seeded in the upper chamber for 24 hours, as described in
the Materials and Methods section, and endothelial cell
Figure 5. Effect of pure antiestrogen ICI 182,780 on 2-ME2– induced upregulation of VEGF-A mRNA expression in GH3 cells. (A) GH3 cells were exposed to 1 M
2-ME2 alone or in combination with 1 M ICI 182,780 for 3 days. Total RNA was isolated and analyzed by Northern blotting using nonradioactive DIG-labeled PCR-
generated probes for VEGF-A and GAPDH. (B) The arbitrary values indicate VEGF-A mRNA concentrations. Data displayed as mean ± SD from three separate
experiments. P value was determined by Student’s t-test. *P < .01 vs control.
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proliferation was determined by measuring the radioactive
thymidine incorporation into the cells. The results indicate
that when BCECs were indirectly cocultured with GH3 cells
exposed to 1 mM 2-ME2, the incorporation of radioactive
thymidine increased by 2.06-fold. In contrast, radioactive
thymidine incorporation levels were unaltered in BCECs
grown in the presence of GH3 cells exposed to a high dose
of 2-ME2 (Figure 8). Moreover, the addition of huMAb-
VEGF-A into the culture reversed the proliferative effect of
GH3 cells that had been exposed to 1 mM 2-ME2.
Discussion
2-ME2 is traditionally an antiproliferative agent and exclu-
sively interacts with proliferative cells modulating target
genes associated with proliferation and apoptosis through
complex basal transcriptional machineries [7,10,16–
19,24,32]. The antiproliferative actions, as well as less toxic
effects, increased the potential therapeutic value of 2-ME2.
Interestingly, results of two recent in vivo and in vitro studies
depart from the existing impression of 2-ME2 action and
indicated that it can, depending on the dosage applied, exert
either proliferative or antiproliferative effects on mammary
tumor growth in rats, and proliferation of human mammary
tumor–derived MCF-7 tumor epithelial cells [12,15]. How-
ever, the precise mechanisms of these actions have not yet
been fully elucidated. Here, we report the novel findings that
2-ME2 is able to activate a signal pathway in steroid-respon-
sive tumor cells, which leads to their growth and survival and
also augments the proliferation of endothelial cells by a
paracrine pathway (Figure 9).
The cell proliferation studies demonstrated that 2-ME2
exhibits biphasic effects on cell proliferation in hormone-
responsive tumor cell lines. Higher dosage (i.e., 5 or 10 mM)
of 2-ME2 inhibits tumor cell proliferation. However, at the
dose of 1 mM, it significantly increases the radioactive
thymidine in ER+ GH3 rat pituitary tumor cells and MCF-7
human mammary tumor cells after 3 days of exposure,
whereas the effect was reversed in ER MIA-PaCa-2 pan-
creatic adenocarcinoma cells. This result is consistent with
previous studies [12]. 2-ME2 does not alter the incorporation
of radioactive thymidine in these cells after acute exposure to
a different dosage of 2-ME2. We therefore sought to deter-
mine the signal that was induced by 2-ME2 and act as a
tumor cell survivor factor. Our recent studies have suggested
that 2-ME2–induced inhibition of estrogen-induced rat pitu-
itary tumor growth is mediated through the downregulation of
VEGF-A expression [14]. This is an essential growth factor
for estrogen-induced tumor angiogenesis and carcinogene-
sis [33], and also modulates the growth of various cancer
cells by the autocrine and paracrine pathways [29,34,35].
VEGF-A mRNA and protein levels can be modulated by
either potent long-acting, or weak or impeded short-acting
estrogens by ER-dependent or ER-independent pathways
[22,36,37]. This suggests that VEGF-A was the signaling
agent responsible for the effects seen with 2-ME2. Because
Figure 6. Effect of 2-ME2 on ER-a– transfected HMECs. (A) ER-a–
transfected cells were exposed to 1 M 2-ME2 or ethanol vehicle for 3 days.
Total RNA was isolated and analyzed by Northern blotting using non-
radioactive DIG-labeled PCR-generated probes for VEGF-A and GAPDH. (B)
The arbitrary values indicate VEGF-A mRNA concentrations. Data displayed
as mean ± SD from three separate experiments. P value was determined by
Student’s t-test. *P < .001 vs control.
Figure 7. Effects of anti –VEGF antibody and recombinant VEGF protein on
the action of 2-ME2 on the proliferation of GH3 and MCF-7 cells.
Exponentially growing cells in DMEM containing 10% serum were exposed
to various concentrations of 2-ME2 in the presence or absence of VEGF
antibodies or recombinant VEGF protein for 3 days, and then cell proliferation
was determined using BrdU ELISA assay. Data displayed as mean ± SD from
three separate experiments. P value was determined by Student’s t-test. *P <
.05 vs control; **P < .01 vs 2-ME2– treated cells.
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2-ME2 has low affinity to bind with classical ER [12,24] and
also because extensive demethylation of 2-ME2 in the body
was reported [15], we have explored the effects of 2-ME2 on
VEGF-A mRNA expression and protein synthesis. The
results obtained indicate that, irrespective of the dosage,
acute exposure (4, 6, or 24 hours) to 2-ME2 increases VEGF-
A transcription in ER+ GH3 cells. However, chronic treatment
invoked a biphasic effect. At the dose of 1 mM 2-ME2, VEGF-
A mRNA and protein levels were increased markedly in GH3
cells as well as in MCF-7 cells. Because the pure estrogen
antagonist, ICI 182,780, was able to counteract the positive
response of VEGF-A to 2-ME2, we suggest that an action of
ER was involved. When cells were exposed to higher dosage
of 2-ME2, the levels of VEGF-A mRNA were markedly
reduced when compared to the basal level of untreated
GH3 and MIA-PaCa-2 cells. Nevertheless, the inhibitory
effect of higher dosage of 2-ME2 was virtually unaltered in
MCF-7 cells. This could be explained by the remarkably low
basal levels of VEGF-A mRNA in MCF-7 cells. The similar
explanation could be applicable to the VEGF-A protein
levels. Together, this study demonstrated a biphasic impact
of 2-ME2 on VEGF-A genes, and enhanced expression of
VEGF-A mRNA and proteins in steroid-responsive cells is
mediated through classical ER. This observation was con-
firmed by additional studies indicating that 2-ME2 was able to
upregulate the VEGF-A expression in ER-a–transfected
HMECs, but not in vehicle-transfected cells or ER MIA-
PaCa-2 pancreatic adenocarcinoma cells where the impact
was basically reversed. There has been a difficulty in estab-
lishing how 2-ME2 modulates the biphasic expression of the
VEGF-A gene in steroid-responsive cells, but it appears that
Figure 8. Effect of 2-ME2– induced VEGF-A in GH3 cells on neighboring
endothelial cell proliferation. The effect was determined by indirect coculture
using Transwell culture system. The detailed experimental procedure has
been described in the Materials and Methods section. Endothelial cell
proliferation was determined by measuring the radioactive thymidine
incorporation using a liquid scintillation counter. Data displayed as mean±SD
from three separate experiments. P value was determined by Student’s t-test.
*P < .05 vs untreated control; **P < .01 vs 2-ME2– treated cells.
Figure 9. A diagram to illustrate the concept of biphasic effects of 2-ME2 and possible mechanism of action of 2-ME2 in ER
+ and hormone-responsive tumor cells.
ER = estrogen receptor-a; P = parent compound.
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the concentration and time of exposure are crucial. One
could argue that when tumor cells are exposed to a low
concentration of 2-ME2, it binds directly to the ER, which
ultimately augments the expression of VEGF-A. Alternative-
ly, tumor cells could produce a catechol estrogen by deme-
thylating 2-ME2, which could bind the ER and increase
VEGF-A transcription (Figure 9). Similar explanations could
be invoked for results with cells exposed to higher dosage of
2-ME2 for short periods of time. As the exposure time
increased, cytotoxic effects might alter functions of multiple
genes and their signaling pathways that ultimately change
the cascade of events associated with the demethylation
process as well as with apoptosis.
If VEGF-A was the agent that was modulated by 2-ME2,
then it would be logical to examine the effect of increasing its
concentration using recombinant protein, or inhibiting its
action by use of a specific anti–VEGF-A antibody. We found
that anti– VEGF-A antibodies partially reversed the prolifer-
ative effect of 2-ME2 in both GH3 and MCF-7 cells. However,
the addition of VEGF-A protein into the culture was able to
block the inhibitory action of 2-ME2. Consequently, these
studies indicate that a threshold level of VEGF-A and its
signal is specific and crucial for protecting tumor cells from
apoptotic death. Because the effect is not absolute, it is likely
that other, as yet undefined, factors are also important in
these events.
VEGF-A, a selective endothelial cell growth factor, is
synthesized and secreted by various tumor cells and by
several transplantable animal tumors [38–40]. Upon secre-
tion from tumor cells, this growth factor may contribute to
angiogenic stimulation by interacting with tumor vessel en-
dothelial cell surface receptors [40,41]. Therefore, we exam-
ined whether 2-ME2–induced VEGF-A expression in tumor
cells is functionally active and enhances the proliferation of
neighboring endothelial cells. The indirect coculture studies
revealed that enhanced expression of VEGF-A released
from tumor cells in response to 2-ME2 interacted with adja-
cent capillary endothelial cells and eventually increased the
endothelial cell proliferation.
In conclusion, this is the first report to indicate that the
bifunctional action of 2-ME2 is directly linked to the VEGF
pathway, as depicted in Figure 9. Although we do not know
yet the immediate, proximate molecular changes that may
require exerting the effect, it is clear that the pathway we
have proposed here will be of importance in explaining the
overall mechanism of action of this molecule. Expectantly,
these studies can further its optimal use for the treatment of
endocrine-related cancers such as breast cancer. Moreover,
therapeutic use of 2-ME2 may be most effective when
administered in combination with an anti–VEGF-A agent,
at least against a subset of breast cancers.
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